PathAI Expands AISight® Clinical Trials Platform with Launch of AIM-HI™ UC and IBDExplore™ for Standardized Histopathology Endpoints

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) — PathAI, a global leader in AI-powered pathology, today announced the strategic expansion of its support of inflammatory bowel disease clinical trials on the AISight® Clinical Trials Platform with the launch of IBDExplore to join AIM-HI UC. This launch marks a significant milestone for drug developers, making these advanced AI solutions immediately available for seamless integration into clinical trial protocols as standardized, reproducible endpoints.

The AISight® Clinical Trials Platform provides a robust, GCP/GCLP-compliant environment that bridges the gap between traditional pathology and computational precision. By launching these tools on AISight® Clinical Trials, PathAI enables biopharma partners to:

• Deploy AI-powered Endpoints: Easily integrate AI-driven histology scores into existing trial workflows to strengthen clinical data packages.
• Hybrid Workflow Support: The platform uniquely supports both manual histology reads and AI-powered computational reads in a single, unified interface.
• Seamless Data Flow: Automated outputs are designed to be trial-ready, providing the scalability needed for global, multi-site studies.

IBDExplore: Deep-Dive Spatial Insights

While AIM-HI UC provides standardized, reproducible histologic scoring, IBDExplore transforms standard H&E-stained histology whole slide images into rich maps of scalable, quantitative spatial insights. When integrated into clinical trial outputs as an exploratory endpoint, IBDExplore empowers researchers to:

• Uncover Mechanism of Action (MoA): Analyze cellular relationships and tissue architecture changes in response to therapy.
• Differentiate in the Market: Identify subtle nuances of response that traditional scoring might miss, providing a competitive edge in therapy positioning.

A Collaborative Effort for Patient Impact

Both tools were developed in partnership with the Foundation for National Institutes of Health (FNIH) Biomarkers Consortium, which leads cross-sector efforts to validate and qualify biomarkers that accelerate the development of new therapeutics and health technologies. The Biomarkers Consortium Mucosal Healing in Ulcerative Colitis project team comprises eight life sciences companies, non-profit foundations, leading academic medical centers, world-renowned key opinion leaders, and regulatory representatives from the FDA, united with the goal of bringing standardized scoring and deeper biological insights to the UC community.

Life sciences leaders within the FNIH project team emphasize that these AI-driven tools provide a level of granularity that was previously unattainable through traditional methods. “The integration of AIM-HI UC and IBDExplore into the clinical trial landscape represents a paradigm shift in how we evaluate treatment efficacy and directly addresses the FNIH project team’s aim to bring standardization to mucosal healing assessment,” said Stephen Laroux, Director – Scientific Research Fellow, Precision Medicine & Immunology at AbbVie and co-chair of the FNIH Mucosal Healing in UC project team. “By leveraging AI to capture subtle histological nuances and spatial patterns that often go undetected by the human eye, we can achieve a more precise and objective understanding of mucosal healing. This technology doesn’t just replicate existing scores; it uncovers insights that help us better differentiate therapeutic impact for patients.”

Echoing the importance of these advancements, Andy Beck, CEO at PathAI said, “The launch of both IBDExplore and AIM-HI UC on the AISight® Clinical Trials platform transforms how we measure success in ulcerative colitis trials. By moving toward deeper insights and automated, reproducible histology, we aren’t just improving data quality, we are accelerating the delivery of life-changing treatments to patients.”

IBDExplore™, AIM-HI™ UC, and AISight® Clinical Trials Platform are For Research Use Only. Not for use in diagnostic procedures.

References

1. Altepeter T, Bhattacharya S, Brosnan-Cashman J, et al. Su1904: Consortium-driven development of pathology foundation model-based approaches for automated scoring of histopathology in ulcerative colitis. Gastroenterology 2025; 169 (1 Supplement): S882.

About PathAI

PathAI is a leading provider of AI-powered pathology solutions that aim to improve the accuracy of histology assessment and accelerate drug development. PathAI’s platform leverages advanced artificial intelligence to analyze and interpret pathology images, providing valuable insights to pathologists, researchers, and pharmaceutical companies. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com and follow us on LinkedIn.

About The Foundation for the National Institutes of Health’s Biomarkers Consortium

The Foundation for the National Institutes of Health’s Biomarkers Consortium leads cross-sector efforts to validate and qualify biomarkers that accelerate the development of new therapeutics and health technologies. The core operations of the Biomarkers Consortium are supported through its contributing membership program, which includes the National Institutes of Health, the U.S. Food and Drug Administration, private industry, and not-for-profit organizations. The FNIH accelerates new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit fnih.org.

Company Contact
Liz Storti
Chief People Officer
elizabeth.storti@pathai.com

Media Contact
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com